Safety, reactogenicity, immunogenicity, and effectiveness of COVID-19 vaccines for pregnant persons: A protocol for a living systematic review and meta-analysis
Author:
Ciapponi Agustín1, Berrueta Mabel1, Ballivian Jamile1, Bardach Ariel1, Mazzoni Agustina1, Anderson Steven2, Argento Fernando J.1, Bok Karin3, Comandé Daniel1, Goucher Erin4, Kampmann Beate5, Parker Edward P. K.5, Rodriguez-Cairoli Federico1, Maria Victoria Santa1, Stergachis Andy6, Voss Gerald7, Xiong Xu4, Zaraa Sabra6, Munoz Flor M.8, Karron Ruth A.9, Gottlieb Sami L.10, Buekens Pierre M.6
Affiliation:
1. Instituto de Efectividad Clínica y Sanitaria (IECS-CONICET) 2. United States Food and Drug Administration 3. National Institute of Allergy and Infectious Diseases (NIAID), Vaccine Research Center 4. School of Public Health and Tropical Medicine, Tulane University 5. The Vaccine Centre, London School of Hygiene and Tropical Medicine 6. School of Pharmacy and School of Public Health, University of Washington 7. Coalition for Epidemic Preparedness Innovations 8. Baylor College of Medicine, Texas Children's Hospital 9. Center for Immunization Research, Bloomberg School of Public Health, Johns Hopkins University 10. Department of Sexual and Reproductive Health and Research, World Health Organization
Abstract
Abstract
Background
Numerous vaccines have been evaluated and approved for coronavirus disease 2019 (COVID-19). Since pregnant persons have been excluded from most clinical trials of COVID-19 vaccines, sufficient data regarding safety of these vaccines for the pregnant persons and their fetus have rarely been available at the time of product licensure. However, as COVID-19 vaccines have been deployed, data on the safety, efficacy or effectiveness, reactogenicity, and immunogenicity of COVID-19 vaccines for pregnant persons and neonates are becoming increasingly available. A living systematic review (LSR) of the safety and effectiveness of COVID-19 vaccines for pregnant persons and newborns could provide information necessary to help guide vaccine policy decisions.
Methods
We aim to conduct a LSR based on biweekly searches of medical databases (e.g., MEDLINE, EMBASE, CENTRAL) and clinical trial registries to systematically identify relevant studies of COVID-19 vaccines for pregnant persons. Pairs of reviewers will independently select, extract data, and conduct risk of bias assessments. We will include randomized clinical trials, quasi-experimental studies, cohort, case-control, cross-sectional studies, and case reports. Primary outcomes will be the safety (i.e., impacts on obstetric and neonatal outcomes), efficacy or effectiveness of COVID-19 vaccines in pregnant persons. Secondary outcomes will be immunogenicity and reactogenicity. We will conduct paired meta-analyses, including pre-specified subgroup and sensitivity analyses, and will use the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach to evaluate the certainty of evidence.
Conclusion
This will be the first living systematic review (LSR) and meta-analysis assessing the safety, reactogenicity, immunogenicity, and effectiveness of COVID-19 vaccines for pregnant persons. An online interactive dashboard for data visualization using Microsoft Power BI will be developed to regularly update and disseminate the latest findings (an in-progress version is available at https://safeinpregnancy.org/lsr/). In addition, the findings will be disseminated through publications and presentations.
Publisher
Research Square Platform LLC
Reference39 articles.
1. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med [Internet]. Massachusetts Medical Society; 2020;382:727–33. Available from: https://doi.org/10.1056/NEJMoa2001017. 2. Guan W-J, Ni Z-Y, Hu Y, Liang W-H, Ou C-Q, He J-X, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med [Internet]. 2020;382:1708–20. Available from: http://dx.doi.org/10.1056/NEJMoa2002032. 3. World Health Organization. WHO Director-General’s opening remarks at the media briefing on COVID-19-11 March 2020. Switzerland: Geneva; 2020. 4. Allotey J, Stallings E, Bonet M, Yap M, Chatterjee S, Kew T, et al. Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis. BMJ [Internet]. 2020;370:m3320. Available from: http://dx.doi.org/10.1136/bmj.m3320. 5. Ellington S, Strid P, Tong VT, Woodworth K, Galang RR, Zambrano LD, et al. Characteristics of Women of Reproductive Age with Laboratory-Confirmed SARS-CoV-2 Infection by Pregnancy Status - United States, January 22-June 7, 2020. MMWR Morb Mortal Wkly Rep [Internet]. 2020;69:769–75. Available from: http://dx.doi.org/10.15585/mmwr.mm6925a1.
|
|